Sara Hägg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Recognitions
Sara Hägg has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Nancy L. Pedersen
Karolinska Institute
48 shared publications - Juulia Jylhävä
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
31 shared publications - Patrik Karl Erik Magnusson
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
23 shared publications - Ida K. Karlsson
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
20 shared publications Yunzhang Wang
Department of Medical Epidemiology and Biostatistics Karolinska Institutet Stockholm Sweden
18 shared publications- Jonathan Ka-Long Mak
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
16 shared publications
Latest Publications
- Open Access
- 15 November 2026
- Published by Wiley in BJU International
Body mass index, waist circumference and association to surgical margins after radical prostatectomy
Objective: To investigate obesity in association with risk of positive surgical margins (PSM) after radical prostatectomy (RP) for prostate cancer. Patients and methods: We used data from Swedish cohorts and registers linked to the National Prostate Cancer Register to identify men who had undergone RP between 2007 and 2021. Relative risks of PSM according to pre‐diagnostic body mass index (BMI) and waist circumference were estimated using logistic regression models. Explorative analyses were conducted by time from diagnosis to surgery, prostate cancer risk category, and calendar period. Results: Of 1344 men with BMI data (measured on average 10 years before diagnosis) who underwent RP, 651 also had waist circumference measurements. Overall, 28% of these men had PSM. Higher BMI and waist circumference were associated with increased risk of PSM; the relative risks were 1.33 (95% confidence interval [CI] 1.08–1.65) per 5 kg/m 2 increment of BMI and 1.26 (95% CI 1.01–1.56) per 10 cm increment of waist circumference. No clear associations were found in the explorative analyses. Conclusions: High BMI and waist circumference were associated with increased risk of PSM. These findings highlight the potential relevance of body size for surgical outcomes and the need to explore possible diagnostic, surgical, and clinical explanations for the observed association.
- 15 November 2026
- Published by Wiley in BJU International
Open AccessBody mass index, waist circumference and association to surgical margins after radical prostatectomy
Objective: To investigate obesity in association with risk of positive surgical margins (PSM) after radical prostatectomy (RP) for prostate cancer. Patients and methods: We used data from Swedish cohorts and registers linked to the National Prostate Cancer Register to identify men who had undergone RP between 2007 and 2021. Relative risks of PSM according to pre‐diagnostic body mass index (BMI) and waist circumference were estimated using logistic regression models. Explorative analyses were conducted by time from diagnosis to surgery, prostate cancer risk category, and calendar period. Results: Of 1344 men with BMI data (measured on average 10 years before diagnosis) who underwent RP, 651 also had waist circumference measurements. Overall, 28% of these men had PSM. Higher BMI and waist circumference were associated with increased risk of PSM; the relative risks were 1.33 (95% confidence interval [CI] 1.08–1.65) per 5 kg/m 2 increment of BMI and 1.26 (95% CI 1.01–1.56) per 10 cm increment of waist circumference. No clear associations were found in the explorative analyses. Conclusions: High BMI and waist circumference were associated with increased risk of PSM. These findings highlight the potential relevance of body size for surgical outcomes and the need to explore possible diagnostic, surgical, and clinical explanations for the observed association.
- Open Access
- 28 October 2026
- Published by Springer Nature in Nature
- p. 1-12
Alzheimer’s disease genetics converges on microglial and neuronal dysregulation
Alzheimer’s disease (AD) is the most common cause of dementia, with global case numbers projected to reach 153 million in 20501. AD is highly heritable, with twin-based heritability estimates of 60–80%2. Although 1,200 causal loci are predicted to exist for AD3, approximately 80 loci have been associated with AD in two recent studies4,5. Low single-nucleotide polymorphism (SNP)-based heritability estimates have prompted the suggestion that little further common-variant risk remains to be found6. Here we analysed data from 109,479 cases, 74,141 proxy cases, 2,131,799 controls and 499,708 proxy controls from diverse ancestries, identifying 118 loci in a multi-ancestry analysis and 9 additional loci in ancestry-specific analyses, 48 of which are new. We identified new AD risk genes, prioritized potential drug targets, and found that genes upregulated in microglia and downregulated in neurons in cases compared with controls were enriched for AD-associated genetic risk. Moreover, we improved polygenic prediction and estimated a SNP heritability of 16%, nearly threefold higher than previous estimates. Together, our findings show that the common-variant contribution to AD has been substantially underestimated, and reveal new molecular and cellular mechanisms as well as specific targets for future drug development research.
- 28 October 2026
- Published by Springer Nature in Nature
- p. 1-12
Open AccessAlzheimer’s disease genetics converges on microglial and neuronal dysregulation
Alzheimer’s disease (AD) is the most common cause of dementia, with global case numbers projected to reach 153 million in 20501. AD is highly heritable, with twin-based heritability estimates of 60–80%2. Although 1,200 causal loci are predicted to exist for AD3, approximately 80 loci have been associated with AD in two recent studies4,5. Low single-nucleotide polymorphism (SNP)-based heritability estimates have prompted the suggestion that little further common-variant risk remains to be found6. Here we analysed data from 109,479 cases, 74,141 proxy cases, 2,131,799 controls and 499,708 proxy controls from diverse ancestries, identifying 118 loci in a multi-ancestry analysis and 9 additional loci in ancestry-specific analyses, 48 of which are new. We identified new AD risk genes, prioritized potential drug targets, and found that genes upregulated in microglia and downregulated in neurons in cases compared with controls were enriched for AD-associated genetic risk. Moreover, we improved polygenic prediction and estimated a SNP heritability of 16%, nearly threefold higher than previous estimates. Together, our findings show that the common-variant contribution to AD has been substantially underestimated, and reveal new molecular and cellular mechanisms as well as specific targets for future drug development research.
- Open Access
- 20 August 2026
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 81 (10)
A generalized approach for estimating the Pace of Aging
Background: Quantifying the rate of aging is essential for understanding age-related physiological decline and predicting late-life outcomes. The Pace of Aging (PoA) framework addresses this by modeling longitudinal changes across multiple biomarkers. However, the original Dunedin PoA assigns equal weight to all biomarkers and was derived from a young cohort with limited mortality follow-up, which restricts its applicability in older populations and in settings where biomarker relevance is uncertain. Methods: We developed a weighted Pace of Aging (wPoA) using data from the Swedish Adoption/Twin Study of Aging (SATSA), a longitudinal cohort of older adults with up to nine waves of biomarker data collected over three decades. Using mixed-effects models, we estimated individual random intercepts and slopes for 10 biomarkers and assigned weights to these random effects based on their association with time-to-mortality. This mortality-informed weighting distinguishes the wPoA from the original Dunedin PoA. Results: We found that wPoA was positively correlated with established biological age predictors and more strongly correlated with low-dimensional predictors such as the Functional Aging Index (FAA) and the Frailty Index (FI). Modest correlations across all considered predictors suggest that each measure captures distinct aspects of biological aging. Conclusions: In conclusion, the wPoA framework introduces a data-driven weighting of random effects and is particularly well-suited for aging cohorts and in settings where marker relevance is uncertain a priori, such as high-dimensional or omics-based contexts. This work provides a foundation for future single-timepoint surrogates that can also be used in settings lacking rich longitudinal data.
- 20 August 2026
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 81 (10)
Open AccessA generalized approach for estimating the Pace of Aging
Background: Quantifying the rate of aging is essential for understanding age-related physiological decline and predicting late-life outcomes. The Pace of Aging (PoA) framework addresses this by modeling longitudinal changes across multiple biomarkers. However, the original Dunedin PoA assigns equal weight to all biomarkers and was derived from a young cohort with limited mortality follow-up, which restricts its applicability in older populations and in settings where biomarker relevance is uncertain. Methods: We developed a weighted Pace of Aging (wPoA) using data from the Swedish Adoption/Twin Study of Aging (SATSA), a longitudinal cohort of older adults with up to nine waves of biomarker data collected over three decades. Using mixed-effects models, we estimated individual random intercepts and slopes for 10 biomarkers and assigned weights to these random effects based on their association with time-to-mortality. This mortality-informed weighting distinguishes the wPoA from the original Dunedin PoA. Results: We found that wPoA was positively correlated with established biological age predictors and more strongly correlated with low-dimensional predictors such as the Functional Aging Index (FAA) and the Frailty Index (FI). Modest correlations across all considered predictors suggest that each measure captures distinct aspects of biological aging. Conclusions: In conclusion, the wPoA framework introduces a data-driven weighting of random effects and is particularly well-suited for aging cohorts and in settings where marker relevance is uncertain a priori, such as high-dimensional or omics-based contexts. This work provides a foundation for future single-timepoint surrogates that can also be used in settings lacking rich longitudinal data.
- Open Access
- 24 July 2026
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (12) , 7170-7177
Associations of general and specific psychopathology factors by age 35 with dementia after age 50: a Swedish population-based sibling comparison study
Multiple psychiatric disorders are associated with later dementia, but it remains unclear whether these associations reflect a shared liability toward all psychiatric conditions (general psychopathology factor) or diagnosis-specific effects (specific psychopathology factors). In this Swedish register-based cohort study, we investigated these questions while adjusting for familial confounding shared by siblings ( N = 2 543 621 individuals, 1 485 880 full-sibling pairs). Exposures were (i) six psychiatric diagnoses recorded by age 35 and (ii) a latent bifactor model fit to these diagnoses that identified one general and three specific (internalizing, externalizing, and psychotic) psychopathology factors. Outcomes were all-cause dementia and Alzheimer’s disease recorded after age 50. For observed psychiatric diagnoses, we estimated between-individual (HR) and within-sibling hazard ratios (HR wn ) using Cox regression; for latent factors, we estimated between-individual (OR) and within-sibling odds ratios (OR wn ) using exploratory structural equation modelling. All psychiatric diagnoses were significantly associated with increased risk of all-cause dementia (HR range 2.03–3.59; HR wn range 1.72–2.94) and Alzheimer’s disease (HR range 1.89–3.47; HR wn range 1.77–3.22). These associations were largely attributable to the general psychopathology factor, even after adjusting for familial confounding (OR wn with 95% CI: 1.25 [1.17–1.32] for dementia; 1.24 [1.16–1.32] for Alzheimer’s disease). After accounting for the general factor, only the psychotic-specific factor remained associated (OR wn with 95% CI: 1.20 [1.07–1.36] for dementia; 1.20 [1.06–1.37] for Alzheimer’s disease). These results suggest that liability toward general psychopathology and, independently, psychotic conditions, by early adulthood might be early markers of increased dementia risk and targets for timely identification and prevention.
- 24 July 2026
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (12) , 7170-7177
Open AccessAssociations of general and specific psychopathology factors by age 35 with dementia after age 50: a Swedish population-based sibling comparison study
Multiple psychiatric disorders are associated with later dementia, but it remains unclear whether these associations reflect a shared liability toward all psychiatric conditions (general psychopathology factor) or diagnosis-specific effects (specific psychopathology factors). In this Swedish register-based cohort study, we investigated these questions while adjusting for familial confounding shared by siblings ( N = 2 543 621 individuals, 1 485 880 full-sibling pairs). Exposures were (i) six psychiatric diagnoses recorded by age 35 and (ii) a latent bifactor model fit to these diagnoses that identified one general and three specific (internalizing, externalizing, and psychotic) psychopathology factors. Outcomes were all-cause dementia and Alzheimer’s disease recorded after age 50. For observed psychiatric diagnoses, we estimated between-individual (HR) and within-sibling hazard ratios (HR wn ) using Cox regression; for latent factors, we estimated between-individual (OR) and within-sibling odds ratios (OR wn ) using exploratory structural equation modelling. All psychiatric diagnoses were significantly associated with increased risk of all-cause dementia (HR range 2.03–3.59; HR wn range 1.72–2.94) and Alzheimer’s disease (HR range 1.89–3.47; HR wn range 1.77–3.22). These associations were largely attributable to the general psychopathology factor, even after adjusting for familial confounding (OR wn with 95% CI: 1.25 [1.17–1.32] for dementia; 1.24 [1.16–1.32] for Alzheimer’s disease). After accounting for the general factor, only the psychotic-specific factor remained associated (OR wn with 95% CI: 1.20 [1.07–1.36] for dementia; 1.20 [1.06–1.37] for Alzheimer’s disease). These results suggest that liability toward general psychopathology and, independently, psychotic conditions, by early adulthood might be early markers of increased dementia risk and targets for timely identification and prevention.
- Open Access
- 21 July 2026
- Published by Public Library of Science (PLoS) in PLOS Aging and Health
- Vol. 1 (1) , e0000023
PLOS Aging and Health: Integrative science of aging across the lifespan
- 21 July 2026
- Published by Public Library of Science (PLoS) in PLOS Aging and Health
- Vol. 1 (1) , e0000023
Open AccessPLOS Aging and Health: Integrative science of aging across the lifespan
- Open Access
- 15 July 2026
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 16 (6) , 1164-1173
Helicobacter pylori infection, peptic ulcer, gastritis and risk of Parkinson's disease: A nationwide matched cohort study
Background: Gastrointestinal symptoms are frequent in Parkinson's disease (PD) and may precede diagnosis by decades, suggesting a possible role in its pathogenesis. Patients with PD have higher rates of Helicobacter pylori ( H. pylori ) infection than the general population, although its potential contribution to PD development remains unclear. Similarly, evidence linking gastritis and peptic ulcer to PD risk is limited. Methods: Using the nationwide ESPRESSO cohort, we investigated associations between H. pylori infection, peptic ulcer, gastritis, and future risk of PD. Individuals diagnosed with these conditions between 1987 or 1990 and 2017 were matched to ≤5 referents from the general population by age, sex, calendar year, and county of residence. Stratified Cox models estimated hazard ratios (HRs), adjusting for country of birth, education, chronic obstructive pulmonary disease, and number of healthcare visits. Incident PD was identified from the National Patient Register. Results: The H. pylori cohort included 48,258 exposed individuals and 231,805 referents; the peptic ulcer cohort included 52,761 exposed individuals and 274,313 referents, while the gastritis cohort included 242,325 exposed individuals and 1,053,688 referents. H. pylori infection (HR: 1.14, 95% CI: 1.02–1.28) and gastritis (HR: 1.14, 95% CI: 1.09–1.19) were associated with a marginally increased PD risk, but we found no significant association in peptic ulcer (HR: 1.08, 95% CI: 0.98–1.19). We observed increased PD risk up to ten years after gastritis diagnosis and no time-varying association for H. pylori and peptic ulcer. Conclusions: H. pylori and gastritis may have some relevance for PD development but are unlikely to be major contributors to its pathogenesis. Plain language summary title: Using gastrointestinal biopsies to explore the link between Helicobacter pylori infection, peptic ulcer, gastritis and Parkinson's disease: findings from a nationwide Swedish cohort study
- 15 July 2026
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 16 (6) , 1164-1173
Open AccessHelicobacter pylori infection, peptic ulcer, gastritis and risk of Parkinson's disease: A nationwide matched cohort study
Background: Gastrointestinal symptoms are frequent in Parkinson's disease (PD) and may precede diagnosis by decades, suggesting a possible role in its pathogenesis. Patients with PD have higher rates of Helicobacter pylori ( H. pylori ) infection than the general population, although its potential contribution to PD development remains unclear. Similarly, evidence linking gastritis and peptic ulcer to PD risk is limited. Methods: Using the nationwide ESPRESSO cohort, we investigated associations between H. pylori infection, peptic ulcer, gastritis, and future risk of PD. Individuals diagnosed with these conditions between 1987 or 1990 and 2017 were matched to ≤5 referents from the general population by age, sex, calendar year, and county of residence. Stratified Cox models estimated hazard ratios (HRs), adjusting for country of birth, education, chronic obstructive pulmonary disease, and number of healthcare visits. Incident PD was identified from the National Patient Register. Results: The H. pylori cohort included 48,258 exposed individuals and 231,805 referents; the peptic ulcer cohort included 52,761 exposed individuals and 274,313 referents, while the gastritis cohort included 242,325 exposed individuals and 1,053,688 referents. H. pylori infection (HR: 1.14, 95% CI: 1.02–1.28) and gastritis (HR: 1.14, 95% CI: 1.09–1.19) were associated with a marginally increased PD risk, but we found no significant association in peptic ulcer (HR: 1.08, 95% CI: 0.98–1.19). We observed increased PD risk up to ten years after gastritis diagnosis and no time-varying association for H. pylori and peptic ulcer. Conclusions: H. pylori and gastritis may have some relevance for PD development but are unlikely to be major contributors to its pathogenesis. Plain language summary title: Using gastrointestinal biopsies to explore the link between Helicobacter pylori infection, peptic ulcer, gastritis and Parkinson's disease: findings from a nationwide Swedish cohort study
- Open Access
- 15 May 2026
- Published by Elsevier in Mechanisms of Ageing and Development
- Vol. 231, 112193
Biological aging as a mediator of the association between air pollution and all-cause mortality and hospitalization: Evidence from the UK Biobank and Lifelines cohorts
- 15 May 2026
- Published by Elsevier in Mechanisms of Ageing and Development
- Vol. 231, 112193
Open AccessBiological aging as a mediator of the association between air pollution and all-cause mortality and hospitalization: Evidence from the UK Biobank and Lifelines cohorts
- Open Access
- 5 May 2026
- Published by Springer Nature in Research Square
Biological aging markers and polygenic risk scores for mortality prediction: a multicohort study
Chronological age is a strong predictor of mortality but does not fully capture heterogeneity in physiological decline. We evaluated whether clinically accessible biological aging (BA) measures and an aging-related polygenic risk score improve all-cause mortality prediction beyond chronological age in two independent cohorts: Swedish TwinGene (n = 9,617; median follow-up 16.70 years) and UK Biobank (n = 179,504; median follow-up 11.83 years). We studied three biomarker-based biological age estimates (PhenoAge, Klemera–Doubal method, and homeostatic dysregulation), a frailty index, leukocyte telomere length, and multivariate aging polygenic risk scores. To focus on age-independent biological age estimates, we used age-adjusted residuals of biomarker-based biological age estimates in discrimination and prediction analyses. We assessed discrimination using receiver operating characteristic analyses and evaluated multivariable prediction using cross-validated ensemble models. Time-to-event associations were estimated using Cox proportional hazards models. Chronological age showed strong univariate discrimination, with area under the ROC curve (AUC) 0.837 in TwinGene and 0.708 in UK Biobank. Among biological aging measures, PhenoAge residual had the highest discrimination (AUC: 0.874 in TwinGene; AUC: 0.624 in UK Biobank), whereas the polygenic risk score showed near-null discrimination (approximately 0.50 in both cohorts). In cross-validated ensemble prediction, adding biological aging measures to chronological age and covariates substantially improved discrimination in TwinGene (AUC: 0.936) and modestly improved discrimination in UK Biobank (AUC: 0.762), while adding the polygenic risk score without biological aging measures produced minimal change. In multivariable Cox models, PhenoAge residual remained independently associated with mortality in both cohorts, whereas the polygenic risk score was not. Clinically biological aging measures, particularly PhenoAge, improve mortality prediction beyond chronological age, while the evaluated aging polygenic risk score adds little incremental predictive value. Cohort differences highlight the importance of evaluating transportability across populations, biomarker panels, and risk horizons.
- 5 May 2026
- Published by Springer Nature in Research Square
Open AccessBiological aging markers and polygenic risk scores for mortality prediction: a multicohort study
Chronological age is a strong predictor of mortality but does not fully capture heterogeneity in physiological decline. We evaluated whether clinically accessible biological aging (BA) measures and an aging-related polygenic risk score improve all-cause mortality prediction beyond chronological age in two independent cohorts: Swedish TwinGene (n = 9,617; median follow-up 16.70 years) and UK Biobank (n = 179,504; median follow-up 11.83 years). We studied three biomarker-based biological age estimates (PhenoAge, Klemera–Doubal method, and homeostatic dysregulation), a frailty index, leukocyte telomere length, and multivariate aging polygenic risk scores. To focus on age-independent biological age estimates, we used age-adjusted residuals of biomarker-based biological age estimates in discrimination and prediction analyses. We assessed discrimination using receiver operating characteristic analyses and evaluated multivariable prediction using cross-validated ensemble models. Time-to-event associations were estimated using Cox proportional hazards models. Chronological age showed strong univariate discrimination, with area under the ROC curve (AUC) 0.837 in TwinGene and 0.708 in UK Biobank. Among biological aging measures, PhenoAge residual had the highest discrimination (AUC: 0.874 in TwinGene; AUC: 0.624 in UK Biobank), whereas the polygenic risk score showed near-null discrimination (approximately 0.50 in both cohorts). In cross-validated ensemble prediction, adding biological aging measures to chronological age and covariates substantially improved discrimination in TwinGene (AUC: 0.936) and modestly improved discrimination in UK Biobank (AUC: 0.762), while adding the polygenic risk score without biological aging measures produced minimal change. In multivariable Cox models, PhenoAge residual remained independently associated with mortality in both cohorts, whereas the polygenic risk score was not. Clinically biological aging measures, particularly PhenoAge, improve mortality prediction beyond chronological age, while the evaluated aging polygenic risk score adds little incremental predictive value. Cohort differences highlight the importance of evaluating transportability across populations, biomarker panels, and risk horizons.
- Open Access
- 22 April 2026
- Published by Springer Nature in Research Square
A twin-based analysis of proteomic organ aging
Organ-specific aging measures have recently gained growing attention. Still, the interpretation of the contributing factors, biological mechanism and relevance of the physiological insights remain unclear. Here, we quantified 639 circulating blood proteins in 6,211 Swedish twins from a population-based cohort (mean age 65±8 years; 57.8% female) to develop organ-specific aging clocks and provide an explorable web application. At sampling, organ aging aligned with lifestyle, clinical and prior disease profiles. Over a 15-year follow-up, organ aging was associated with age-related disease, multimorbidity, healthspan, and mortality, capturing both organ-specific and systemic effects. Greater burden of aged organs even marked poorer health trajectories. The twin-based analyses revealed moderate heritability and persistence of key health associations. Associations with mortality remained robust (cardiovascular age HR 2.20[1.69–2.85]; FDR<0.001) even within monozygotic pairs. These twin-based findings support proteomic organ aging as an indicator of biologically meaningful processes beyond inherited liability and its measures remains responsive to non-shared biological influences that shape aging and disease risk.
- 22 April 2026
- Published by Springer Nature in Research Square
Open AccessA twin-based analysis of proteomic organ aging
Organ-specific aging measures have recently gained growing attention. Still, the interpretation of the contributing factors, biological mechanism and relevance of the physiological insights remain unclear. Here, we quantified 639 circulating blood proteins in 6,211 Swedish twins from a population-based cohort (mean age 65±8 years; 57.8% female) to develop organ-specific aging clocks and provide an explorable web application. At sampling, organ aging aligned with lifestyle, clinical and prior disease profiles. Over a 15-year follow-up, organ aging was associated with age-related disease, multimorbidity, healthspan, and mortality, capturing both organ-specific and systemic effects. Greater burden of aged organs even marked poorer health trajectories. The twin-based analyses revealed moderate heritability and persistence of key health associations. Associations with mortality remained robust (cardiovascular age HR 2.20[1.69–2.85]; FDR<0.001) even within monozygotic pairs. These twin-based findings support proteomic organ aging as an indicator of biologically meaningful processes beyond inherited liability and its measures remains responsive to non-shared biological influences that shape aging and disease risk.
- Open Access
- 2 April 2026
- Published by Springer Nature in GeroScience
The MetaboHealth score is 40% heritable and is influenced by frailty status, BMI, and smoking in Swedish twins
The MetaboHealth score, a metabolomics-based biomarker trained on mortality, is associated with ageing-related phenotypes and morbidity, but its heritable component is still uncertain. Understanding genetic versus environmental contributions is essential for its utility as an intervention-responsive biomarker. Hence, the aim of this study was to estimate heritability of the MetaboHealth score in the large Swedish TwinGene cohort and evaluate interactions with modifiable lifestyle factors and health outcomes. We analysed 12,256 twins (55% female; mean age 64.8 years at blood draw) with Nightingale Health-based metabolomics data, followed until February 2024 (median follow-up time of 16.2 years). We subsequently estimated the heritability of the score using additive genetic (A), shared environmental (C), and unique environmental (E) (ACE) modelling via Cholesky decomposition in 1,370 monozygotic and 3,381 dizygotic twin pairs. Cox regression was used to assess mortality associations, with sensitivity analyses stratified by age, smoking, body mass index (BMI), and frailty. The MetaboHealth score was significantly associated with all-cause mortality (Hazard ratio (HR) = 1.91, 95% confidence interval (CI): 1.73–2.11; P = 1.32 × 10⁻ 38 ) in Swedish twins and its heritable component was estimated to be 40% (95% CI: 37–43%), with 57.5% of the variance attributable to unique environment and 2.5% to shared environment. Lifestyle factors and health outcomes, including BMI (P = 8.36 × 10⁻⁶), smoking (P = 0.009), and frailty (P = 6.55 × 10⁻ 4 ), were associated with the score. Notably, mortality associations were strongest in younger adults (HR = 2.76 in individuals ≤ 65 years of age versus HR = 1.77 in individuals > 65 years of age) and smokers (HR = 2.16 in smokers versus HR = 1.59 in non-smokers). Moreover, analyses of monozygotic twins showed reduced score correlations in discordant pairs, where one twin was non-frail and the other pre-frail or frail (r 2 concordant = 0.184 versus r 2 discordant = 0.119; P = 0.042). In conclusion, with only 40% of its variance fixed by genetics, the MetaboHealth score is predominantly environmentally modifiable. Its heightened sensitivity to mortality risk in younger adults and smokers, and association with frailty status and BMI, supports its use as a biomarker for precision interventions in healthy ageing. Graphical Abstract
- 2 April 2026
- Published by Springer Nature in GeroScience
Open AccessThe MetaboHealth score is 40% heritable and is influenced by frailty status, BMI, and smoking in Swedish twins
The MetaboHealth score, a metabolomics-based biomarker trained on mortality, is associated with ageing-related phenotypes and morbidity, but its heritable component is still uncertain. Understanding genetic versus environmental contributions is essential for its utility as an intervention-responsive biomarker. Hence, the aim of this study was to estimate heritability of the MetaboHealth score in the large Swedish TwinGene cohort and evaluate interactions with modifiable lifestyle factors and health outcomes. We analysed 12,256 twins (55% female; mean age 64.8 years at blood draw) with Nightingale Health-based metabolomics data, followed until February 2024 (median follow-up time of 16.2 years). We subsequently estimated the heritability of the score using additive genetic (A), shared environmental (C), and unique environmental (E) (ACE) modelling via Cholesky decomposition in 1,370 monozygotic and 3,381 dizygotic twin pairs. Cox regression was used to assess mortality associations, with sensitivity analyses stratified by age, smoking, body mass index (BMI), and frailty. The MetaboHealth score was significantly associated with all-cause mortality (Hazard ratio (HR) = 1.91, 95% confidence interval (CI): 1.73–2.11; P = 1.32 × 10⁻ 38 ) in Swedish twins and its heritable component was estimated to be 40% (95% CI: 37–43%), with 57.5% of the variance attributable to unique environment and 2.5% to shared environment. Lifestyle factors and health outcomes, including BMI (P = 8.36 × 10⁻⁶), smoking (P = 0.009), and frailty (P = 6.55 × 10⁻ 4 ), were associated with the score. Notably, mortality associations were strongest in younger adults (HR = 2.76 in individuals ≤ 65 years of age versus HR = 1.77 in individuals > 65 years of age) and smokers (HR = 2.16 in smokers versus HR = 1.59 in non-smokers). Moreover, analyses of monozygotic twins showed reduced score correlations in discordant pairs, where one twin was non-frail and the other pre-frail or frail (r 2 concordant = 0.184 versus r 2 discordant = 0.119; P = 0.042). In conclusion, with only 40% of its variance fixed by genetics, the MetaboHealth score is predominantly environmentally modifiable. Its heightened sensitivity to mortality risk in younger adults and smokers, and association with frailty status and BMI, supports its use as a biomarker for precision interventions in healthy ageing. Graphical Abstract